SG11202007251XA - Spiro-lactam nmda receptor modulators and uses thereof - Google Patents
Spiro-lactam nmda receptor modulators and uses thereofInfo
- Publication number
- SG11202007251XA SG11202007251XA SG11202007251XA SG11202007251XA SG11202007251XA SG 11202007251X A SG11202007251X A SG 11202007251XA SG 11202007251X A SG11202007251X A SG 11202007251XA SG 11202007251X A SG11202007251X A SG 11202007251XA SG 11202007251X A SG11202007251X A SG 11202007251XA
- Authority
- SG
- Singapore
- Prior art keywords
- spiro
- nmda receptor
- receptor modulators
- lactam nmda
- lactam
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862624218P | 2018-01-31 | 2018-01-31 | |
US201862718107P | 2018-08-13 | 2018-08-13 | |
PCT/US2019/016098 WO2019152678A1 (en) | 2018-01-31 | 2019-01-31 | Spiro-lactam nmda receptor modulators and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202007251XA true SG11202007251XA (en) | 2020-08-28 |
Family
ID=65494516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202007251XA SG11202007251XA (en) | 2018-01-31 | 2019-01-31 | Spiro-lactam nmda receptor modulators and uses thereof |
Country Status (15)
Country | Link |
---|---|
US (1) | US20210047324A1 (en) |
EP (1) | EP3746442A1 (en) |
JP (2) | JP2021512109A (en) |
KR (1) | KR20200115610A (en) |
CN (1) | CN112218866A (en) |
AU (1) | AU2019215049A1 (en) |
BR (1) | BR112020015666A2 (en) |
CA (1) | CA3089559A1 (en) |
CL (1) | CL2020001990A1 (en) |
IL (1) | IL276330A (en) |
MX (1) | MX2020008106A (en) |
PE (1) | PE20211455A1 (en) |
PH (1) | PH12020551140A1 (en) |
SG (1) | SG11202007251XA (en) |
WO (1) | WO2019152678A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2019001318A (en) | 2016-08-01 | 2019-07-01 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof. |
CA3031539C (en) | 2016-08-01 | 2023-11-28 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
PE20190501A1 (en) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | NMDA ESPIRO-LACTAM MODULATORS AND METHODS OF USE OF THE SAME |
BR112019001768A2 (en) | 2016-08-01 | 2019-06-11 | Aptinyx Inc | spiro-lactam receptor modulators and their uses |
CA3089561A1 (en) | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
PE20211001A1 (en) | 2018-02-27 | 2021-06-01 | Incyte Corp | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS INHIBITORS OF A2A / A2B |
MX2020012376A (en) | 2018-05-18 | 2021-03-09 | Incyte Corp | Fused pyrimidine derivatives as a2a / a2b inhibitors. |
AU2019297361B2 (en) | 2018-07-05 | 2024-06-27 | Incyte Corporation | Fused pyrazine derivatives as A2A / A2B inhibitors |
TWI829857B (en) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors |
US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
WO2024054919A1 (en) * | 2022-09-08 | 2024-03-14 | Tenacia Biotechnology (Hong Kong) Co., Limited | Spiro-lactam nmda receptor modulators and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011003015A (en) * | 2008-09-18 | 2011-11-18 | Univ Northwestern | Nmda receptor modulators and uses thereof. |
TWI466885B (en) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | Nitrogen-containing spiro cyclic compounds and pharmaceutical use thereof |
US9101612B2 (en) * | 2010-02-11 | 2015-08-11 | Northwestern University | Secondary structure stabilized NMDA receptor modulators and uses thereof |
MX2015009778A (en) * | 2013-01-29 | 2016-02-09 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof. |
CA2898863A1 (en) * | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
HRP20221545T1 (en) * | 2013-01-29 | 2023-03-03 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
US9708335B2 (en) * | 2013-01-29 | 2017-07-18 | Apytinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
JP6531042B2 (en) * | 2013-01-29 | 2019-06-12 | アプティニックス インコーポレイテッド | Spirolactam NMDA receptor modulators and uses thereof |
JP6823083B2 (en) * | 2016-05-19 | 2021-01-27 | アプティニックス インコーポレイテッド | Spirolactam NMDA Receptor Modulators and Their Use |
WO2017201285A1 (en) * | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
JP2022092387A (en) * | 2020-12-10 | 2022-06-22 | キヤノン株式会社 | Image formation apparatus |
-
2019
- 2019-01-31 MX MX2020008106A patent/MX2020008106A/en unknown
- 2019-01-31 BR BR112020015666-3A patent/BR112020015666A2/en not_active Application Discontinuation
- 2019-01-31 KR KR1020207024903A patent/KR20200115610A/en unknown
- 2019-01-31 CN CN201980018351.6A patent/CN112218866A/en active Pending
- 2019-01-31 JP JP2020541807A patent/JP2021512109A/en active Pending
- 2019-01-31 EP EP19706076.7A patent/EP3746442A1/en active Pending
- 2019-01-31 SG SG11202007251XA patent/SG11202007251XA/en unknown
- 2019-01-31 CA CA3089559A patent/CA3089559A1/en active Pending
- 2019-01-31 AU AU2019215049A patent/AU2019215049A1/en active Pending
- 2019-01-31 WO PCT/US2019/016098 patent/WO2019152678A1/en unknown
- 2019-01-31 US US16/966,176 patent/US20210047324A1/en not_active Abandoned
- 2019-01-31 PE PE2020001149A patent/PE20211455A1/en unknown
-
2020
- 2020-07-27 IL IL276330A patent/IL276330A/en unknown
- 2020-07-28 PH PH12020551140A patent/PH12020551140A1/en unknown
- 2020-07-30 CL CL2020001990A patent/CL2020001990A1/en unknown
-
2023
- 2023-11-10 JP JP2023192455A patent/JP2024019396A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
PE20211455A1 (en) | 2021-08-05 |
WO2019152678A1 (en) | 2019-08-08 |
KR20200115610A (en) | 2020-10-07 |
CA3089559A1 (en) | 2019-08-08 |
AU2019215049A1 (en) | 2020-09-17 |
JP2021512109A (en) | 2021-05-13 |
US20210047324A1 (en) | 2021-02-18 |
CL2020001990A1 (en) | 2021-03-26 |
BR112020015666A2 (en) | 2021-02-23 |
EP3746442A1 (en) | 2020-12-09 |
IL276330A (en) | 2020-09-30 |
JP2024019396A (en) | 2024-02-09 |
PH12020551140A1 (en) | 2021-05-31 |
MX2020008106A (en) | 2020-09-25 |
CN112218866A (en) | 2021-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276332A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
IL276330A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
ZA201807731B (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
IL264514B (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
IL282257A (en) | Androgen receptor modulators and methods for their use | |
IL286107A (en) | Spiro-lactam nmda receptor modulators and usesthereof | |
IL264488A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
EP3490994B8 (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
IL276295A (en) | Chemokine receptor modulators and uses thereof | |
EP3558318A4 (en) | Nmda receptor modulators and uses thereof | |
DK3830092T3 (en) | Heteroaromatic nmda receptor modulators and uses thereof | |
ZA202105847B (en) | Mtroc modulators and uses thereof | |
IL268263B (en) | Estrogen receptor modulators | |
RS60834B1 (en) | Heteroaromatic nmda receptor modulators and uses thereof | |
HK1245259A1 (en) | Pyridopyrimidinones and their use as nmda receptor modulators | |
IL289575A (en) | Modulators of the nmda receptor |